Advances in bronchoscopic lung volume reduction using endobronchial valves

孙康,潘蕾,金发光
DOI: https://doi.org/10.3760/cma.j.cn131368-20200410-00274
2020-01-01
Abstract:Because of hyperinflation, patients with severe emphysema can result in hypoxia symptoms and even respiratory failure.Severe emphysema is an irreversible progressive chronic respiratory disease in which drug treatment has poor effects.After continuous exploration, lung volume reduction surgery and endoscopic lung volume reduction got a great development.Bronchoscopic lung volume reduction using endobronchial valves is currently the only reversible endoscopic lung volume reduction, which meets the criteria of clinical application.It has the same benefit as surgical lung volume reduction, but it is less invasive and has less complications and lower mortality.It has been recommended by the GOLD and UK/NICE guidelines as a treatment option for patients with severe emphysema.Endobronchial valves can cause target lung lobe atelectasis, reduce hyperinflation, and ultimately improve pulmonary function and clinical symptoms.The success of the operation and the maximum benefit of the patients depend on the accurate selection of patient and the target lobe and negative collateral ventilation between the target lobe and the adjacent lobe.Either heterogeneous or homogeneous emphysema has been proven to benefit from this procedure.Prediction and active management of postoperative complications can minimize the risk of surgical complications.
What problem does this paper attempt to address?